Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to $351000.0.

  • Pulse Biosciences' Other Accumulated Expenses rose 7038.83% to $351000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $351000.0, marking a year-over-year increase of 7038.83%. This contributed to the annual value of $188000.0 for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Pulse Biosciences reported Other Accumulated Expenses of $351000.0 as of Q3 2025, which was up 7038.83% from $212000.0 recorded in Q2 2025.
  • Pulse Biosciences' 5-year Other Accumulated Expenses high stood at $2.2 million for Q1 2021, and its period low was $167000.0 during Q2 2024.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $270000.0 (2021), whereas its average is $404473.7.
  • Per our database at Business Quant, Pulse Biosciences' Other Accumulated Expenses skyrocketed by 178620.69% in 2021 and then crashed by 8651.74% in 2022.
  • Over the past 5 years, Pulse Biosciences' Other Accumulated Expenses (Quarter) stood at $513000.0 in 2021, then grew by 11.31% to $571000.0 in 2022, then plummeted by 67.08% to $188000.0 in 2023, then changed by 0.0% to $188000.0 in 2024, then soared by 86.7% to $351000.0 in 2025.
  • Its last three reported values are $351000.0 in Q3 2025, $212000.0 for Q2 2025, and $283000.0 during Q1 2025.